Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University.  The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Genmab

Vivo Capital

Rock Springs Capital

Samsara BioCapital

Sofinnova Investments

Surveyor Capital

Novo Holdings

Pfizer Venture Investments

Pivotal bioVenture Partners

RA Capital Management

Bolt Biotherapeutics, Inc. 

#BoltBio management will be in New York for the Guggenheim Partners Healthcare Talks Biotech Conference. We look forward to connecting in person!

Today is #WorldCancerDay, and members of #TeamBolt are running in support of The DONNA Foundation and its Fight to FINISH #BreastCancer. Learn more about the DONNA Foundation here: https://bit.ly/4b5oMaJ

We’re just 1 week away from DONNA Marathon Weekend! #BoltBio is hosting this year’s Curb Crew, and encourages spectators to ring their cowbells loudly to support the runners. Learn more about The DONNA Foundation and their work to FINISH #breastcancer: https://bit.ly/48PVsUk 

NASDAQ:BOLT

Bolt Biotherapeutics

Last Close

1.14

19/04 20:00

Market Cap

40.62M

Beta: 0.99

Volume Today

55.03K

Avg: 250.78K

PE Ratio

−0.60

PFCF: −0.56

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics

Please Sign In To Use The Chat